Macquarie has lifted its earnings estimates over a three-year period and boosted its target price for pathology player Healius on the back of a surge in COVID-19 tests.
COVID-19 PCR testing has increased substantially over the past month leading Macquarie analyst David Bailey to increase his forecasts for the first half of 2022 for Healius, which also runs imaging services and a day hospitals business.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
